Westpac Banking Corp I Mab Transaction History

Westpac Banking Corp

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$8.27 - $18.43 $872,054 - $1.94 Million	-105,448 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$12.54 - $46.93 $29,594 - $110,754	2,360 Added 2.29%	105,448 $1.71 Million
Q4 2021 Feb 08, 2022	BUY	$45.28 - $74.5 $1.35 Million - $2.22 Million	29,864 Added 40.78%	103,088 $4.89 Billion
Q3 2021 Oct 27, 2021	BUY	$57.18 - $84.43 $4.19 Million - $6.18 Million	73,224 New	73,224 $5.31 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $78.9M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Westpac Banking Corp, based on Form 13F filings with the SEC.

Stay updated on Westpac Banking Corp with notifications on news.